Medicoinvestor's  Instablog

Send Message
  • Invest In The Revolutionizing New Biomarker NGAL. (And Beat Abbott And Inverness To The Pot Of Gold) 0 comments
    Oct 26, 2012 11:03 AM | about stocks: ABT, ALR, RHHBYEGY

    If you are reading this, chances are that you already know the great potential that NGAL holds. Not only as a revolutionizing Biomarker.

    But you might ask yourself , "is it possible to invest in a public listed company, where NGAL is the MAIN business, and where the potential in NGAL is yet to be calculated into the price of its shares?"

    We believe that Bioporto Diagnostics A/S is just that investment case that you have been looking for. To help you make your own decision, we at have made this presentation.

    But instead of only praising NGAL/BioPorto ( , we at Medicoinvestor also feel it is our duty to inform you - about the challenges ahead, especially in regards to different patent issues, and ongoing lawsuits…

    The best indication that NGAL is interesting - is the vigor with which the Cutoff-Patent (already twice endorsed by EPO - and granted in India, Japan, Brazil etc.) is being fought by Abbott and Alere.

    Right now the stock is in a limbo, and the price is fixed between upper and lower estimates, in our view primarily as a result of the pending patent issue.

    Before investing - you will be advised to ask you self what kind of investor you are. If you are an "early-bird-catches-the-worm" type of investor, now could be the time to make a purchase.

    But of course that is just our opinion, you need to make your own judgments in regards to whether BioPorto will win or lose the core patent, and not just take our opinion for granted.

    On the other hand - if your focus in on safety and capital preservation , you could wait until the ruling of the EPO, in regards to the patent. If the patent is revoked, the stock will tumble - anything from 25-50%. If the patent is maintained - then we see an immediate upside of the same percentages (or more)

    Bear in mind that regardless if it turns out good or bad for Bioporto, they still market the only NGAL test, usable on almost all of the major brands analyzers, and have established distributionschannels in all the major countries, including India, China and the EU. (In the US, design of a FDA survey is ongoing)

    In time, they will become one of the major players on the NGAL marked.

    Stocks: ABT, ALR, RHHBYEGY
Back To Medicoinvestor's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.